In addition to the quality of life, a study of HER2-negative breast cancer patients with stage 2/3 breast cancer were randomized to 48-h fasting (24-h prior to and 24-h after chemotherapy) to evaluate chemotherapy-induced toxicity. This evidence concerns the gene ERBB2 and breast carcinoma.